Lecture 1
Leading cause of cancer death in USA: Lung cancer / Most common in USA: Prostate cancer for men and breast cancer for women
Most common cause of cancer in jordan
Males: Lung cancer followed by colorectal cancer
Females: Breast cancer followed by colorectal cancer
Environmental factors are the predominant cause of cancer
Stomach cancer is common in Japan
One third of deaths from cancer are caused by obesity, physical inactivity, smoking, alcohol and low veg diet. • Smoking is responsible for 20% of cancer deaths.
Most common childhood tumors: leukemias, lymphomas, CNS tumors and soft tissue and bone sarcomas.
The difference between a neoplastic and non-neoplastic process is the presence of specific mutations in neoplasms.
Nevi (nevus) are benign tumors of melanocytes / Melanoma is a malignant tumor of melanocytes
(exceptions) Some benign neoplasms can be dangerous (like brain tumors) / Some malignant tumors are highly curable , e:g Hodgkin lymphoma
lipoma: benign tumour arising from fat tissue / Adenoma= benign epithelial neoplasm forming glands or neoplasm derived from glands
Polyp: mass projecting above mucosal surface (MACROscopic)
Teratoma: mixed tumor containing elements of more than one germ cell layer / Mature = benign immature = malignant
Hamartoma: Mass of disorganized tissue indigenous to a particular site
Choristoma: Heterotopic rests of cells, normal in appearance but present in an abnormal location (Congenital anomaly)
Malignant OMAs: Melanoma • Seminoma • Lymphoma • Mesothelioma • Multiple myeloma ( MMM SL)
Lecture 2
Tumour stage is the single most important prognostic factor.
Anaplasia is a hallmark of cancer / Tripolar mitosis = Mercedes sign
**Exceptions: Leiomyoma of uterus: can grow rapidly during pregnancy due to high estrogen level (shrink in menopause)
Local invasion is the second most important feature to differentiate benign from malignant neoplasms
Metastasis is the most important feature of malignancy
Basal cell carcinoma of skin doesn’t metastasize
•CNS tumors rarely metastasize
• Bone =osteogenic sarcoma usually found to be metastasized before discovering the primary tumor
Routes of metastatic spread
• 1. seeding within body cavities (Ovarian cancer through peritoneal cavity)
2. lymphatiC (Carcinomas)
• 3. hematogenouS (Sarcomas) (Liver and lungs are the most common sites of spread)
Lecture 3
Genes involved in cancer:
Proto Oncogenes/ Tumor suppressor genes/ DNA repair Genes/ genes that regulate Apoptosis/ genes that affect the interaction between tumour cells and host cells (esp relation with immune system)
oncogenes are dominant // Important oncogenes : RAS and ABL
Tumor suppressor genes are recessive genes // RB gene and TP53 gene
Genes that regulate apoptosis or DNA repair may be dominant or recessive.
Occur mainly in haematogenous neoplasms
Translocations can cause cancer if they increase expression of a protooncogene. This can happen by two mechanisms:
• 1. Removing the proto-oncogene from its normal, regulated locus to a new position where it becomes under influence of a highly active promoter. (MYC moved close to IG locus)
• 2. Translocation forms a new fusion gene that encodes a novel protein. (ABL-BCR fusion creating a new tyrosine kinase resulting in leukemia) (Philadelphia chromosome) (t9:22)
Genes can be amplified by: 1-homogeneously stained region (HSR) = increased copies of the gene present within the chromosome :2.Double minutes: extra copies of the gene separated from the chromosome.
Deletions: More in non-hematopoietic solid tumors // Second most common karyotypic abnormality. // Result in loss of tumor suppressor genes • 2 copies of the tumor suppressor gene need to be lost, usually one by point mutation and another by deletion
Aneuploidy: • Result from errors of the mitotic checkpoint
microRNAs: inhibit gene expression post-transcriptionally = repress translation or cleave mRNA
• Epigenetics are reversible, heritable changes in gene expression that occur without mutation // occurs through DNA methylation and histone modification
DNA methylation= more methyl groups lead to more silencing.
• 1.Global DNA hypomethylation : increases expression of genes. Also causes chromosomal instability
• 2.Selective promoter hypermethylation of tumor suppressor genes: silenced
Lecture 4:
For cancer to develop we need: a- 8 hallmarks // b- 2 enablers // c- correct microenvironment
The eight hallmarks • 1. self sufficiency in growth signals • 2. insensitivity to growth inhibitory signals • 3. evasion of cell death • 4. limitless replicative potential • 5. sustained angiogenesis • 6. ability to invade and metastasize • 7. reprogramming of metabolism • 8. evasion of the immune system
Enablers: 1-genomic instability 2-inflammation /// Tumor microenvironment: This is obtained from the host cells:Stromal cells, mainly fibroblasts and pericytes
1.Self sufficiency in growth signals
Growth factors:
• GF can be synthesized by tumor cells or host stromal cells
• glioblastomas produce PDGF and express its receptor
Growth receptors:
2 ways
1- overexpression of receptor
2- mutant receptor protein
Gene encoding her2/neu is amplified in 25-30% of breast cancers and adenocarcinoma of lung, ovary and salivary gland
• High level of HER2/Neu protein in breast cancer worsens prognosis (results in more proliferation)
Signal Proteins:
• Main signal transducing proteins involved: RAS and ABL
RAS | ABL |
1- most common mutated gene in humans (in 30% of cancers) 2- higher incidence in colon and pancreatic cancers | ABL-BCR translocation Results in a hybrid gene The hybrid gene produces novel tyrosine kinase which is always active and stimulating proliferation…This is the Philadelphia chromosome |
Uses 2 pathways: 1- RAF-MAPK // 2-PI3K AKT mTOR RAF mutated in 60% of melanomas | ABL-BCR pathway activates all the downstream signals of ras |
Activated (mutated) by 1- point mutation in GTP binding pocket 2- Mutation in GTPase activity | Found in CML (chronic myelogenous leukemia) Imatinab/gleevec (kinase inhibitors) used to treat CML |
Nuclear transcription factors:
Most common in humans: MYC // MYC activates cyclins and CDK and inhibits CDKI
Cyclins: D E A B
Cyclin D activated in many tumors mainly lymphomas
Second hallmark of cancer: insensitivity to growth inhibitors:
Main genes/pathways: 1. RB gene 2. TP53 gene 3. TGF beta pathway 4. Contact inhibition 5. APC gene
RB gene: directly or indirectly inactivated in most cancers // negative regulator of cell cycle (regulates G1/S checkpoint)
Works by binding E2F preventing it from transcribing Cyclin E. it does so by
RB is active when HYPOphosphorylated and active when phosphorylated
Growth signals cause cyclin D expression. Cyclin D complexes with CDKs… these complexes phosphorylate and inactivate RB.
certain viruses can deactivate RB by hyper-phosphorylating it
RB is named after a tumor called: Retinoblastoma // 60 % sporadic, 40% familial - In familial cases the predisposition to develop the tumor is inherited as an autosomal dominant trait
RB gene is found on chromosome 13 (13q14)locus // People with inherited RB have increased risk of other cancers.. Mainly osteosarcomas and soft tissue sarcomas
Loss of normal cell cycle control is found in all tumors through mutations of RB, cyclin D, CDK4 or CDKN2A (which is a CDKI)
TP53:
P53 monitors internal stress whereas RB senses external signals
P53 is triggered by several stresses: anoxia, inappropriate oncogene activity (MYC or RAS) or DNA damage.